Logo

Vir and Alnylam Anticipate the Initiation of Clinical Study Assessing VIR-2703 By the Year End

Share this

Vir and Alnylam Anticipate the Initiation of Clinical Study Assessing VIR-2703 By the Year End

Shots:

  • The companies reported the selection of DC for VIR-2703 (ALN-COV) targeting SARS-CoV-2 genome and intend to meet US FDA & other regulatory authorities for IND filing with a plan to commence human studies by the end of 2020
  • In Oct- 2017- Alnylam and Vir entered into an exclusive license agreement to develop and commercialize RNAi therapeutics for infectious diseases- with an option to develop up to four additional infectious disease products
  • VIR-2703 is an inhaled siRNA targeting SARS-CoV-2 genome and is the first DC selected in Vir’s expanded collaboration with Alnylam for up to four RNAi potential therapeutics for COVID-19

Click here to­ read full press release/ article | Ref: Businesswire | Image: Alnylam

Related News: Vir and Alnylam Expand Their Existing Collaboration to Develop RNAi Therapeutics Targeting Host Factors for COVID-19


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions